Equivalence of Bioidentical Hormones from Soy (*Glycine max*) and Wild Yam (*Dioscorea* spp.)

FOCUS ON PURITY, STABILITY, SAFETY, AND EFFICACY

www.fagron.com

Fagron
personalizing medicine

Summary

Highlights

- **Hormones derived from plant sources**: Wild yam (*Dioscorea* spp.) and soy (*Glycine max*) can serve as natural sources for synthesizing bioidentical and non-bioidentical sexual hormones, utilizing their precursors such as diosgenin and phytosterols.
- **Chemical identity to natural hormones**: When processed under stringent pharmaceutical conditions, bioidentical hormones derived from wild yam and soy are chemically and functionally identical to human endogenous hormones.
- **Advanced purification techniques**: Fagron ensures the removal of impurities and allergens through multi-step processes, including hydrolysis, crystallization, and chromatography, achieving pharmaceutical-grade purity.
- **Rigorous analytical verification**: Techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy, mass spectrometry (MS), and High-Performance Liquid Chromatography (HPLC) confirm structural integrity, functional groups, and molecular weight.
- **Clinical effectiveness and safety**: Bioidentical hormones synthesized from either sources exhibit equivalent receptor-binding affinity and biological activity.
- **Hypoallergenic hormones**: Hormones derived from soy are free from allergenic proteins and other common allergens, making them suitable for sensitive populations.
- **Stability across sources**: Hormones from both wild yam and soy show comparable stability profiles under varying conditions, ensuring efficacy and shelf life.
- **Interchangeability of sources**: The choice between wild yam and soy as starting materials depends on availability and cost, as both yield indistinguishable final products when processed with the same rigor.
- **Fagron's commitment to quality**: With adherence to Good Manufacturing Practices (GMP), Fagron ensures consistency, reproducibility, and regulatory compliance in hormone synthesis, delivering premium-quality products and ensuring that **Fagron's hormones meet the highest standards in the market**.

1. Introduction

Sexual hormones, such as progesterone and testosterone, are essential for various physiological processes, including reproduction, metabolism, and overall health. As the demand for hormone replacement therapies and bioidentical hormones continues to grow, the choice of starting material for their synthesis has gained significant attention. Plant-based sources, particularly wild yam (*Dioscorea* spp.) and soy (*Glycine max*), are commonly utilized due to their natural abundance of precursors suitable for hormone production.

Wild yam is rich in diosgenin, a steroidal saponin that serves as an efficient precursor for the synthesis of bioidentical hormones. Soy, on the other hand, contains isoflavones such as daidzein and genistein, which can also be chemically converted into bioidentical hormones. While these plant-derived sources differ in their natural composition, advancements in pharmaceutical synthesis ensure that both can yield high-quality bioidentical hormones when processed under stringent conditions. This document explores the chemical properties, quality aspects, functionality, effectiveness, and safety profiles of hormones synthesized from wild yam and soy, highlighting their equivalency when manufactured with the same rigor.

2. Main steroid hormones used in Bioidentical Hormone Replacement Therapy

2.1. Estrone

Estrone (E1) (Figure 1) is one of the three primary estrogens produced in the human body and plays a particularly significant role during the menopausal transition. While estradiol (E2) is the most active estrogen during reproductive years, its production declines markedly as women enter menopause. In contrast, estrone becomes the predominant circulating estrogen in postmenopausal women. This shift is primarily due to the increased synthesis of estrone in adipose tissue through the aromatization of androgens, a process facilitated by the enzyme aromatase, which converts androgens into estrone within peripheral tissues. Unlike estradiol, which is predominantly produced in the ovaries, estrone relies on peripheral conversion.[1]



Figure 1. Estrone (E1).

A key physiological effect of estrone during menopause is its role in altering body fat distribution. As estradiol levels decline, estrone's relative increase is associated with a shift in fat storage from the hips to the abdomen, leading to central adiposity. This accumulation of visceral fat is not merely a cosmetic issue; it is clinically significant as it correlates with an increased risk of metabolic syndrome, cardiovascular diseases, and insulin resistance. The interplay between reduced estradiol and increased estrone levels affects adipose tissue metabolism, contributing to these changes in body composition and associated health risks.[2,3]

Given its weaker estrogenic properties and less desirable metabolic effects, estrone is not typically prioritized in hormone replacement therapy protocols. Clinicians tend to favor the supplementation of estradiol, which offers a more potent estrogenic effect and a broader range of beneficial outcomes.

2.2. Estradiol

Estradiol (E2) (Figure 2) is the most potent and biologically active form of estrogen, playing a central role in numerous physiological processes, particularly during the reproductive years. Its influence extends beyond reproductive health, impacting a variety of systems throughout the body, making it a critical focus in hormone replacement therapy.[4]



Figure 2. Estradiol (E2).

Estradiol's high estrogenic activity is characterized by its strong affinity for estrogen receptors, enabling it to exert substantial effects across multiple tissues. During the reproductive period, estradiol is the dominant estrogen, regulating the menstrual cycle, supporting ovarian follicle maturation, facilitating fertility, and sustaining pregnancy.[5]

Due to its pivotal role, estradiol replacement therapy is frequently recommended during menopause, a phase when endogenous production of estradiol declines significantly. This decline is associated with various menopausal symptoms, including vasomotor symptoms like hot flashes and night sweats, as well as long-term risks such as osteoporosis and cardiovascular disease. Estradiol supplementation has been shown to alleviate these symptoms effectively, offering a protective effect against these conditions and thereby enhancing the quality of life for postmenopausal women.[6,7]

2.3. Estriol

Estriol (E3) (Figure 3) is the least potent of the three primary estrogens, characterized by its relatively weak estrogenic activity. Despite its lower affinity for estrogen receptors compared to estradiol, estriol plays a distinctive role in the context of HRT, offering therapeutic advantages in specific clinical scenarios, especially for postmenopausal women.[8]



Figure 3. Estriol (E3).

Endogenously, estriol is synthesized primarily during pregnancy, where it is produced in significant quantities by the placenta. Outside of pregnancy, estriol arises from the metabolism of more potent estrogens, such as estradiol and estrone, through peripheral conversion. This metabolic pathway allows the body to modulate estrogenic activity by converting stronger estrogens into estriol, which exerts a more moderate influence on estrogen-sensitive tissues. This capacity for conversion provides a mechanism for fine-tuning estrogenic effects, particularly in tissues where minimal estrogenic stimulation is beneficial.[9,10]

In clinical practice, estriol is frequently utilized in topical formulations, where its weaker estrogenic activity presents an advantage. For instance, estriol creams or gels are often applied to alleviate skin dryness and reduce facial wrinkles, as well as to manage vaginal atrophy—a common condition in postmenopausal women. Local application of estriol in these cases can effectively restore the health and elasticity of vaginal tissues without significantly elevating systemic estrogen levels, thereby minimizing the risk of adverse effects associated with systemic estrogen exposure.[9,10]

2.4. Progesterone

Progesterone (P4) (Figure 4) is a key hormone with critical roles in both reproductive health and overall physiology, particularly in women. Its functions extend beyond its well-known role in pregnancy, influencing various tissues and systems throughout the body.



Figure 4. Progesterone.

One of progesterone's primary roles is in modulating the endometrial environment during the menstrual cycle. During the luteal phase, progesterone promotes secretory changes in the endometrium, counteracting the proliferative effects of estrogens. Estrogens stimulate the growth of the endometrial lining, but unchecked

proliferation can result in pathological conditions such as endometrial hyperplasia and, potentially, endometrial carcinoma. Progesterone mitigates this risk by inducing the maturation and stabilization of the endometrium, creating a balanced environment that is prepared for the potential implantation of a fertilized ovum.[11]

During pregnancy, progesterone is indispensable for maintaining a stable uterine environment. It supports the integrity of the uterine lining and suppresses uterine contractions, thereby reducing the risk of preterm labor. The hormone's ability to relax the smooth muscle tissue of the uterus is crucial for sustaining pregnancy to term. As a result, progesterone levels rise substantially throughout gestation, reflecting its role in ensuring optimal conditions for fetal development.[12]

In addition to its effects on the uterus, progesterone plays a significant role in the preparation of the mammary glands for lactation. During pregnancy, progesterone, in conjunction with estrogens and prolactin, facilitates the development of the mammary tissue, setting the stage for milk production. Following childbirth, the sharp decline in progesterone triggers the onset of lactation, enabling breastfeeding.[13]

Beyond these roles, progesterone serves as a precursor for the synthesis of other steroid hormones. It undergoes metabolism into androgens, estrogens, and corticosteroids within the body, depending on enzymatic activity and physiological needs. This capacity for conversion underscores progesterone's versatility and its critical role in maintaining hormonal equilibrium within the endocrine system.[11]

2.5. Testosterone

Although testosterone (T) (Figure 5) is often primarily associated with male physiology, it is a vital hormone for the overall health and well-being of both men and women. Its regulatory effects extend beyond the reproductive system, influencing a range of physiological processes that are critical to maintaining physical and mental health.



Figure 5. Testosterone.

One of the most recognized roles of testosterone is in the regulation of libido. Adequate levels of testosterone are essential for maintaining sexual desire in both sexes. Low levels of this hormone can result in diminished libido and may contribute to other forms of sexual dysfunction, underscoring its importance in sexual health.[14,15]

Beyond its effects on sexual function, testosterone is crucial for the development and maintenance of muscle mass. It has a well-documented anabolic effect, promoting muscle protein synthesis and enhancing muscle growth and strength. Additionally, testosterone helps to reduce body fat, which is why it is often associated with athletic performance and physical vitality. By supporting the accrual of lean muscle mass, testosterone increases the basal metabolic rate, contributing to a more favorable body composition. This anabolic role is particularly significant as individuals age, helping to counteract the age-related decline in muscle mass and strength.[14,15]

Testosterone also exerts beneficial effects on cardiovascular health. It has been shown to support lipid metabolism, aiding in the reduction of cholesterol levels and the regulation of blood pressure—both of which are critical factors in cardiovascular risk management. Studies indicate that optimal testosterone levels are associated with a reduced risk of cardiovascular events, likely due to its role in promoting vasodilation, improving blood flow, and supporting overall vascular health.[16,17]

In addition to its cardiovascular benefits, testosterone plays a pivotal role in bone metabolism. It stimulates osteoblastic activity, leading to increased bone density and mass, which is crucial for the prevention of osteoporosis, particularly in older populations. Testosterone's ability to enhance calcium retention in bone tissue further underscores its role in maintaining skeletal integrity and reducing the risk of fractures.[18]

Lastly, testosterone is important for cognitive function. It has been shown to support cognitive processes, including memory, attention, and spatial abilities. Emerging research suggests that testosterone may have neuroprotective properties, potentially offering some protection against cognitive decline as individuals age. This highlights its relevance not only for physical health but also for maintaining cognitive acuity and mental clarity throughout the aging process.[19]

3. Steroid hormone biosynthesis

As a reference for comparison the synthetic route for those hormones from wild yam and soy, it is important to also understand the biosynthesis of the same hormones in the human body. The biosynthesis of all steroid hormones originates from cholesterol, which acts as the precursor molecule for the production of various steroid derivatives (Figure 6). The initial conversion of cholesterol into pregnenolone, catalyzed by the enzyme cholesterol side-chain cleavage enzyme (P450scc), is a critical step, marking the entry into the steroidogenic pathway. From this point, the pathway diverges based on tissue-specific enzymatic activity, leading to the synthesis of distinct classes of steroids.[20]



Figure 6. The steroid hormones biosynthesis in the human body. Adapted[14]

In the progesterone synthesis pathway (highlighted in the yellow section), pregnenolone is converted into progesterone through the action of 3β-hydroxysteroid dehydrogenase (3β-HSD). Progesterone serves as a precursor to other steroid hormones, including cortisol and aldosterone, depending on the expression of specific enzymes within different tissues.

The synthesis of androgens, including testosterone, is represented in the left part of the grey section. Progesterone and its derivatives are further metabolized by 17α-hydroxylase and 17,20-lyase, producing DHEA and androstenedione — key precursors to testosterone. The conversion of androstenedione into testosterone is facilitated by 17β-hydroxysteroid dehydrogenase (17β-HSD). Testosterone can undergo further conversion into dihydrotestosterone (DHT) through 5α-reductase, particularly in tissues where DHT exerts more potent androgenic effects.

The purple section illustrates the synthesis of glucocorticoids and mineralocorticoids, including cortisol and aldosterone, which are essential for stress response, metabolism, and electrolyte homeostasis. This pathway includes the conversion of 11-deoxycorticosterone to corticosterone, and subsequently to aldosterone, mediated by aldosterone synthase in the adrenal cortex.

Estrogens are synthesized through the aromatization of androgens, specifically testosterone and androstenedione, by the enzyme aromatase, leading to the production of estradiol and estrone (represented in the brownish section, to the right of the grey section). These estrogens are integral to reproductive function and are synthesized in multiple tissues, including the ovaries, adrenal glands, adipose tissue, skin, and, during pregnancy, the placenta.

Estrogens are synthesized primarily in the ovaries, with additional contributions from the adrenal glands, adipose tissue, skin, and the placenta during pregnancy. Progesterone is mainly produced in the ovaries, though smaller amounts are synthesized by the adrenal glands and the placenta during pregnancy. Testosterone production occurs in the ovaries and adrenal glands in women, while in men, the testes serve as the primary site of production.

A detailed understanding of these biosynthetic pathways is essential for clinicians when considering hormone replacement therapies, as it highlights the interconnected nature of steroid hormones. Modulating one hormone can have cascading effects on others; for example, exogenous testosterone administration may elevate estrogen levels through aromatization, while supplemental progesterone can influence glucocorticoid and mineralocorticoid synthesis depending on the patient's enzymatic profile.

Central to steroid hormone biosynthesis is the steroid nucleus derived from cholesterol — a structure composed of four interconnected carbon rings, forming a 17-carbon cyclopentanoperhydrophenanthrene framework. Modifications to this structure, such as the addition or removal of functional groups, lead to the synthesis of various steroid hormones, including testosterone, estradiol, estriol, and progesterone.

Despite their distinct physiological roles, steroid hormones share significant chemical similarities. For example:

- **Testosterone and Estradiol**: Differ by a single functional group; testosterone has a keto group at the 17th position, while estradiol has a hydroxyl group, resulting in dramatically different biological effects despite their similar structures.
- **Progesterone and Testosterone**: Share a common steroid backbone but differ in functional groups and the positioning of double bonds, leading to varied receptor interactions and biological activities.
- **Estradiol and Estriol**: Both are estrogens, but estriol, with an additional hydroxyl group at the 16th position, is less potent than estradiol, yet plays a crucial role during pregnancy in maintaining the uterine environment.

The ability of the body to interconvert these hormones is a vital aspect of both physiology and therapeutic intervention. For instance:

- **Aromatase** converts testosterone into estradiol, a process particularly relevant in adipose tissue, where unregulated conversion can contribute to estrogen dominance.
- **5α-Reductase** transforms testosterone into DHT, a potent androgen crucial for male sexual development but associated with conditions like androgenic alopecia and benign prostatic hyperplasia when overproduced.
- **17-Hydroxysteroid Dehydrogenase (17-HSD)** mediates the conversion of androstenedione to testosterone and estrone to estradiol, influencing the balance between androgens and estrogens.

These conversion processes underscore the importance of selecting the appropriate chemical form of a hormone in therapy. Minor structural variations can significantly alter receptor affinities, metabolic pathways, and half-lives, thereby influencing clinical outcomes. For instance, synthetic progestins differ chemically from bioidentical progesterone, leading to divergent effects on lipid metabolism, mood regulation, and breast cancer risk due to their distinct receptor interactions.

Maintaining hormonal equilibrium is crucial for optimal health. The body's natural conversion pathways serve as mechanisms for balancing hormone levels, compensating for surpluses or deficiencies. Disruption of this balance—whether through pathological states or inappropriate hormone therapy—can result in significant clinical consequences. For example, an excess of estradiol relative to progesterone may lead to estrogen dominance, associated with symptoms such as weight gain, mood disturbances, and an elevated risk of certain cancers. Conversely, excessive androgenic activity can disrupt estrogen levels, contributing to conditions like polycystic ovary syndrome (PCOS) or hormonal acne.

This intricate understanding of steroid hormone biosynthesis informs the rationale behind choosing bioidentical formulations and precise dosing in clinical practice. By respecting the body's natural hormone chemistry, clinicians can ensure that hormone replacement therapy supports the endocrine system's balance, optimizing therapeutic efficacy and minimizing adverse outcomes.

4. Comparison of chemical routes for hormones from wild yam and soy

4.1. Production of hormones from wild yam

Wild yam serves as an abundant source of diosgenin, a steroidal sapogenin whose molecular structure closely resembles that of human steroid hormones. Diosgenin, the primary compound in wild yam, is isolated through a series of steps that include hydrolysis of the yam extracts to remove non-steroidal impurities, followed by chromatographic purification to obtain pure diosgenin. Once isolated, diosgenin becomes the foundation for the synthesis of various steroid hormones, with progesterone and testosterone being key examples. These two molecules serve as "models" for the synthesis of other hormones, including estradiol and estriol, due to their representative pathways and similar structural modifications.

The synthesis process begins with the chemical transformation of diosgenin into pregnenolone, a pivotal intermediate in steroid biosynthesis. This involves acetylation, oxidation, and reduction reactions that modify the diosgenin structure while preserving its steroidal framework. Marker's modified degradation process provides the foundational chemistry for this transformation and highlights the pathway leading to progesterone and testosterone. Despite advancements in alternative methods, this remains one of the most widely used processes in the industry worldwide.

Progesterone Synthesis Pathway

The pathway for synthesizing progesterone from diosgenin involves acetylation as the initial step (Figure 7). Diosgenin is treated with acetic anhydride (Ac_2O) at elevated temperatures (200 °C), resulting in a fully acetylated intermediate. This acetylation protects the hydroxyl group and activates the molecule for subsequent oxidation. The acetylated diosgenin is then subjected to oxidation with chromium trioxide (CrO_3), which converts the intermediate into 16-dehydropregnenolone acetate (16-DPA). This oxidation step introduces a ketone group at a crucial position, enhancing its chemical versatility.[21,22]

From 16-DPA, the molecule undergoes base-mediated deacetylation using potassium hydroxide (KOH), preparing it for further oxidation. The next step involves oxidation with chromium trioxide in pyridine (CrO_3, Py), which converts the hydroxyl group into a ketone, yielding progesterone. This series of steps ensures the precise modification of the steroid nucleus to produce a structurally identical compound to endogenous progesterone.



Figure 7. Marker's Modified Degradation Process for the progesterone production from diosgenin isolated from wild yam.

Testosterone Synthesis Pathway

To synthesize testosterone, the intermediate 16-DPA undergoes a slightly different sequence of reactions (Figure 8). The first step involves reacting 16-DPA with hydroxylamine (NH_2OH) to form an oxime derivative. This reaction introduces a nitrogen functional group, which is subsequently tosylated using p-toluenesulfonyl chloride (p-TsCl) in an acidic medium. Hydrolysis of the tosyl oxime removes protective groups and exposes the steroid nucleus for further modifications.

The intermediate is then subjected to a base-mediated deacetylation step using potassium hydroxide (KOH), followed by oxidation with chromium trioxide in pyridine (CrO_3, Py). These steps yield a ketone intermediate, which is selectively reduced using sodium borohydride ($NaBH_4$) in ethanol (EtOH), resulting in testosterone. The final product retains the precise molecular structure and functional groups characteristic of natural testosterone.

The processes for progesterone and testosterone synthesis from diosgenin serve as templates for the production of other steroid hormones, including estradiol and estriol. The pathways involve strategic chemical modifications, such as selective oxidation, reduction, and functional group transformations, to achieve structural identity with endogenous hormones. **By utilizing diosgenin as a precursor, these synthesis pathways provide a scalable and reliable method for producing bioidentical steroid hormones**.



Figure 8. Alternative route from Marker's Modified Degradation Process for the production of testosterone from 16-DPA originated from diosgenin from wild yam.

4.2. Production of hormones from soy

Phytosterols, including β-sitosterol, stigmasterol, campesterol, and brassicasterol, are abundant in soy and serve as critical intermediates in the synthesis of steroid hormones due to their structural resemblance to cholesterol. These compounds are derived through the extraction of soybean oil, which is rich in sterols. The extraction process involves mechanical pressing or solvent-based methods to obtain crude oil. This crude oil undergoes saponification with a strong alkali, such as sodium hydroxide, which hydrolyzes triglycerides into glycerol and free fatty acids. During this reaction, the unsaponifiable fraction containing the phytosterols is separated. The resulting fraction is further purified using distillation, crystallization, or chromatography to isolate sterols such as β-sitosterol, stigmasterol, campesterol, and brassicasterol in their pure forms.

Progesterone Synthesis Pathway

The synthesis of progesterone from stigmasterol begins with stigmasteryl acetate, a derivative of stigmasterol (Figure 9). The first step involves bromination using bromine (Br_2), which adds bromine atoms across the double bond in the side chain, forming a dibromo intermediate. This intermediate undergoes ozonolysis (O_3), cleaving

the aliphatic side chain and oxidizing it into a carboxylic acid group, simplifying the structure to the steroidal core with a terminal carboxylic acid.

The carboxylic acid is then reduced to an alcohol using zinc in acetic acid, eliminating the oxygenated side chain while refining the molecule's framework. To prepare for further transformation, the hydroxyl group is replaced with a benzylidene moiety through a reaction with benzaldehyde, forming a phenyl-substituted intermediate. Bromination followed by chromium trioxide (CrO_3) oxidation converts the intermediate into a ketone at the C-3 position while maintaining the steroid nucleus. The final step employs Oppenauer oxidation, which selectively oxidizes the hydroxyl group at the C-17 position into a ketone, yielding progesterone. This process preserves the steroidal structure while introducing functional groups essential for progesterone's hormonal activity. This efficient pathway illustrates the strategic use of bromination, ozonolysis, reduction, and oxidation in modifying stigmasterol into bioidentical progesterone.



Figure 9. Organic synthesis of progesterone from stigmasterol derivatives from soy.

Testosterone Synthesis Pathway

Once isolated, phytosterols are chemically or enzymatically converted into androstenedione, a key intermediate in the production of testosterone (Figure 10). The conversion begins with the cleavage of the aliphatic side chain at the C-17 position of the sterol molecule, a step facilitated by enzymatic or chemical oxidation mediated by hydroxysteroid dehydrogenases (HSDs). This reaction introduces a ketone group at the C-20 position, simplifying the side chain structure. Subsequent oxidation removes the remaining chain, yielding a steroidal framework resembling androstenedione. In later steps, the hydroxyl group at the C-3 position is oxidized into a ketone by enzymes such as 3-ketosteroid-1-dehydrogenase (KstD). Meanwhile, structural adjustments at the C-4 and C-5 positions are carried out by enzymes like 3-ketosteroid-9α-hydroxylase (Ksh), which stabilize the double bond and preserve the steroid nucleus.

Subsequently, the production of testosterone from androstenedione involves targeted chemical modifications to transform this precursor into the bioactive hormone (Figure 11). Androstenedione undergoes two main stages in this process: esterification and reduction. In the esterification stage, the ketone group at the C-17 position is temporarily protected by forming an ester intermediate, stabilizing the molecule for the subsequent reduction. In the second stage, reduction and hydrolysis, the ester group at the C-17 position is selectively reduced to a hydroxyl group using reducing agents or enzymes such as 17β-hydroxysteroid dehydrogenase. This step transforms the C-17 ketone into the hydroxyl group characteristic of testosterone. Hydrolysis removes any residual protective groups, completing the transformation and restoring the molecule to its active form.



Figure 10. Conversion of β-sitosterol, a phytosterol derived from vegetable oils, into androstenedione and testosterone through enzymatic pathways.[24]

This pathway highlights the role of androstenedione as an efficient precursor for testosterone synthesis. The enzymatic or chemical modifications maintain the steroidal nucleus while enabling precise structural changes necessary for the conversion. The result is bioidentical testosterone, structurally and functionally equivalent to its natural counterpart, suitable for human physiology and pharmaceutical applications.



Figure 11. Conversion of β-sitosterol, a phytosterol derived from vegetable oils, into androstenedione and testosterone through enzymatic pathways.[24]

4.3. Purification of final molecules

The primary goal of chemical synthesis, regardless of the starting material, is to achieve structural and functional identity with natural human hormones. This is accomplished through precise chemical transformations and rigorous verification at every stage to ensure that the resulting compounds match their endogenous counterparts in structure and biological activity. Advanced analytical techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy and mass spectrometry (MS) play a vital role in confirming molecular structure, functional groups, and molecular weight, while chromatographic methods like High-Performance Liquid Chromatography (HPLC) ensure purity and homogeneity by identifying and quantifying components. These processes are supported by stringent quality control measures, including stability testing and adherence to regulatory standards, to guarantee consistency, reproducibility, and safety. By applying these techniques meticulously, hormones synthesized from wild yam and soy are made structurally and functionally indistinguishable from their natural equivalents, ensuring efficacy and reliability in clinical and therapeutic applications.

4.4. Fagron's commitment to hormone purity

Fagron employs a comprehensive chemical synthesis process to ensure its hormones achieve structural and functional identity with natural human hormones. This involves precise chemical transformations and rigorous verification at every stage to confirm that the resulting compounds are biologically indistinguishable from their endogenous counterparts. Detailed identification of hormone structures, such as progesterone and testosterone, is achieved using advanced analytical techniques, as outlined in Fagron's structure identification reports.

NMR spectroscopy plays a key role in this process. The structure identification reports for both testosterone and progesterone highlight the use of 1H-NMR, 13C-NMR, and HSQC techniques to confirm the arrangement of functional groups, double bonds, and stereochemistry. For testosterone, NMR data confirmed the presence of 19 carbon atoms and 28 hydrogens, with chemical shifts consistent with the structure of 17β-hydroxyandrost-4-en-3-one. Similarly, for progesterone, NMR confirmed the presence of 21 carbon atoms, including characteristic signals for the α, β-unsaturated ketone at C-3 and the ketone at C-20.

Mass spectrometry further validates molecular weights and formulas. For testosterone, the positive-ion ESI-MS spectrum revealed a peak at m/z 289.2170, consistent with its formula $C_{19}H_{28}O_2$. For progesterone, MS analysis confirmed a molecular weight of 314.2, matching its formula $C_{21}H_{30}O_2$. Infrared spectroscopy (IR) complements these techniques by confirming functional groups. For testosterone, the IR spectrum showed stretching vibrations for hydroxyl groups and α, β-unsaturated ketones, while progesterone's spectrum confirmed key vibrations for ketone groups and alkenes.

Chromatographic techniques like HPLC ensure the purity, homogeneity, and absence of impurities in intermediates and final products. Fagron's adherence to rigorous quality assurance protocols guarantees reproducibility, regulatory compliance, and product stability under various conditions. By combining these advanced analytical techniques with meticulous process controls, Fagron produces hormones derived from soy or wild yam that are structurally and functionally identical to natural human hormones, ensuring their clinical efficacy, safety, and reliability in therapeutic applications.

5. Comparison of quality and functionality for hormones from wild yam and soy

Manufacturing under Good Manufacturing Practices (GMP) ensures that the production environment minimizes contamination risks. Both wild yam and soy hormones, when processed with equal rigor, yield products that meet or exceed these stringent standards, ensuring uniform quality regardless of the starting material.

The stability of bioidentical hormones is also critical for their efficacy and shelf life. Stability testing evaluates the hormones under various conditions, including temperature, humidity, and light exposure. Hormones synthesized from both wild yam and soy exhibit comparable stability profiles when processed with pharmaceutical-grade techniques.

Bioidentical hormones synthesized from either source are structurally identical to endogenous human hormones, ensuring:

- **Receptor binding affinity**: Both wild yam- and soy-derived hormones demonstrate identical binding properties to human hormone receptors. This is a direct result of their structural equivalence to natural hormones. The receptor-hormone interaction triggers the same cascade of biological responses, such as gene activation or enzymatic regulation, ensuring consistent and predictable physiological effects.
- **Biological activity**: The biological activity of hormones synthesized from wild yam and soy is indistinguishable when synthesized to meet pharmaceutical-grade standards. Both sources produce hormones capable of effectively regulating processes like reproduction, metabolic function, and hormonal balance. This equivalency is validated through bioassays and clinical trials, confirming that the source material does not influence functional outcomes when processing rigor is maintained.

Clinical studies indicate no significant difference in the effectiveness of bioidentical hormones derived from wild yam or soy when synthesized with the same rigor. Both types of hormones alleviate symptoms associated with hormonal imbalances, such as menopausal symptoms or infertility, with equivalent outcomes. **In fact, clinical studies do not even mention the source of the hormones, as it does not influence the clinical outcomes**.

Effectiveness is measured through clinical endpoints, such as symptom reduction, hormonal blood levels, and patient-reported outcomes. Both wild yam- and soy-derived hormones consistently meet therapeutic goals, confirming their interchangeability in clinical practice. This reinforces the notion that processing standards, rather than the source material, dictate the therapeutic equivalency of the final product.

6. Safety considerations

6.1. Toxicity

Hormones synthesized from wild yam and soy are deemed safe when stringent purification processes are applied. The potential presence of residual solvents, byproducts, or impurities from synthesis is mitigated through advanced manufacturing techniques such as recrystallization and chromatography. Both starting materials undergo rigorous testing to ensure the absence of harmful contaminants, and finished products are subjected to toxicity testing in preclinical studies to confirm their safety for human use. Pharmaceutical-grade hormones synthesized from either source exhibit no toxic effects when administered within recommended doses. Regular pharmacovigilance monitoring post-market ensures continued safety in clinical use.[25–27]

6.2. Allergenicity

Allergic reactions to hormones derived from wild yam or soy are extremely rare due to the high levels of purity achieved during the manufacturing and synthesis processes. While unprocessed soy products are known to pose allergenic risks to individuals sensitive to soy proteins, the materials used in hormone production, such as those derived from soy phytosterols, are entirely free from allergenic components.

According to the allergen statement provided for Fagron's raw materials derived from soy, the final products are confirmed to be free of gluten, wheat, soy proteins, dairy, egg products, nuts, sulfites, artificial flavors, and genetically modified organisms (GMOs).

The production process involves chemical synthesis that eliminates all plant proteins and other potential allergens, ensuring that the end products, such as testosterone and other hormones derived from soy, are hypoallergenic. This comprehensive removal of allergens makes these materials suitable for individuals with soy allergies, as no allergenic residues remain in the final hormone product. These rigorous processing standards ensure that the final hormones are not only structurally identical to their natural human counterparts but also safe for use in sensitive populations.

6.3. Long-term use

Long-term safety profiles of hormones derived from wild yam and soy are equivalent, supported by extensive clinical studies and decades of therapeutic use. These studies demonstrate the absence of adverse effects on liver function, cardiovascular health, or other systemic markers when bioidentical hormones are used appropriately.[3,28–39]

Ongoing research continues to validate their safety, particularly for hormone replacement therapies in menopausal women and other long-term treatments.[40–54]

7. Conclusion

Wild yam and soy are both viable starting materials for the synthesis of bioidentical sexual hormones. When synthesized under strict pharmaceutical standards, the final products are chemically, functionally, and therapeutically equivalent. The rigorous processes involved in manufacturing ensure that the safety, purity, and effectiveness of these hormones meet the highest pharmaceutical standards. The selection of the starting material—wild yam or soy—is largely a matter of availability and production preferences, as the end products are indistinguishable when processed correctly.

Furthermore, the reliance on advanced quality control measures ensures that both sources produce bioidentical hormones suitable for clinical use across a wide range of applications. This interchangeability allows healthcare providers and manufacturers to make decisions based on factors such as sustainability, cost, and local availability without compromising the quality or performance of the final products.

The scientific consensus underscores the importance of adhering to stringent manufacturing standards and robust regulatory compliance. As such, the success of bioidentical hormone therapies depends more on reliable suppliers and rigorous production practices than on the choice of precursor material, offering reassurance to patients and practitioners alike that both wild yam and soy can reliably contribute to safe and effective hormonal treatments.

References

1. Thijssen JHH, Wiegerinck MAHM, Mulder G, Poortman J. On the Biological Activity of Estrone in vivo. In: ; :220-229. doi:10.1159/000401996
2. Kim C, Harlow SD, Zheng H, McConnell DS, Randolph JF. Changes in androstenedione, dehydroepiandrosterone, testosterone, estradiol, and estrone over the menopausal transition. *Womens Midlife Health*. 2017;3(1):9. doi:10.1186/s40695-017-0028-4
3. Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. *J Clin Endocrinol Metab*. 2021;106(1):1-15. doi:10.1210/clinem/dgaa764
4. Kumar A, Banerjee A, Singh D, et al. Estradiol: A Steroid with Multiple Facets. *Hormone and Metabolic Research*. 2018;50(05):359-374. doi:10.1055/s-0044-100920
5. Bao A, Liu R, van Someren E, Hofman M, Cao Y, Zhou J. Diurnal rhythm of free estradiol during the menstrual cycle. *Eur J Endocrinol*. 2003;148(2):227-232. doi:10.1530/eje.0.1480227
6. Graham S, Archer DF, Simon JA, Ohleth KM, Bernick B. Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins. *Gynecological Endocrinology*. 2022;38(11):891-910. doi:10.1080/09513590.2022.2118254
7. Farkas S, Szabó A, Hegyi AE, et al. Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions. *Biomedicines*. 2022;10(4):861. doi:10.3390/biomedicines10040861
8. Ali ES, Mangold C, Peiris AN. Estriol: emerging clinical benefits. *Menopause*. 2017;24(9):1081-1085. doi:10.1097/GME.0000000000000855
9. Lephart ED, Naftolin F. Menopause and the Skin: Old Favorites and New Innovations in Cosmeceuticals for Estrogen-Deficient Skin. *Dermatol Ther (Heidelb)*. 2021;11(1):53-69. doi:10.1007/s13555-020-00468-7
10. Rzepecki AK, Murase JE, Juran R, Fabi SG, McLellan BN. Estrogen-deficient skin: The role of topical therapy. *Int J Womens Dermatol*. 2019;5(2):85-90. doi:10.1016/j.ijwd.2019.01.001
11. Kolatorova L, Vitku J, Suchopar J, Hill M, Parizek A. Progesterone: A Steroid with Wide Range of Effects in Physiology as Well as Human Medicine. *Int J Mol Sci*. 2022;23(14):7989. doi:10.3390/ijms23147989
12. Vaisbuch E, Erez O, Romero R. Physiology of Progesterone. In: *Progestogens in Obstetrics and Gynecology*. Springer International Publishing; 2015:1-32. doi:10.1007/978-3-319-14385-9_1
13. Taraborrelli S. Physiology, production and action of progesterone. *Acta Obstet Gynecol Scand*. 2015;94(S161):8-16. doi:10.1111/aogs.12771
14. Tauchen J, Jurášek M, Huml L, Rimpelová S. Medicinal Use of Testosterone and Related Steroids Revisited. *Molecules*. 2021;26(4):1032. doi:10.3390/molecules26041032
15. Dandona P, Dhindsa S, Ghanim H, Saad F. Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review. *Diabetes Obes Metab*. 2021;23(1):18-28. doi:10.1111/dom.14206
16. Cittadini A, Isidori AM, Salzano A. Testosterone therapy and cardiovascular diseases. *Cardiovasc Res*. 2022;118(9):2039-2057. doi:10.1093/cvr/cvab241
17. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. *New England Journal of Medicine*. 2023;389(2):107-117. doi:10.1056/NEJMoa2215025
18. Corona G, Vena W, Pizzocaro A, et al. Testosterone supplementation and bone parameters: a systematic review and meta-analysis study. *J Endocrinol Invest*. 2022;45(5):911-926. doi:10.1007/s40618-021-01702-5
19. Yeap BB, Flicker L. Testosterone, cognitive decline and dementia in ageing men. *Rev Endocr Metab Disord*. 2022;23(6):1243-1257. doi:10.1007/s11154-022-09728-7
20. Strauss JF. The Synthesis and Metabolism of Steroid Hormones. In: *Yen & Jaffe's Reproductive Endocrinology*. Elsevier; 2014:66-92.e3. doi:10.1016/B978-1-4557-2758-2.00004-4
21. Marker RE. Sterols. CV. The Preparation of Testosterone and Related Compounds from Sarsasapogenin and Diosgenin. *J Am Chem Soc*. 1940;62(9):2543-2547. doi:10.1021/ja01866a077
22. Marker RE, Tsukamoto T, Turner DL. Sterols. C. Diosgenin. *J Am Chem Soc*. 1940;62(9):2525-2532. doi:10.1021/ja01866a072
23. Zhao A, Zhang X, Li Y, et al. Mycolicibacterium cell factory for the production of steroid-based drug intermediates. *Biotechnol Adv*. 2021;53:107860. doi:10.1016/j.biotechadv.2021.107860
24. Nunes V, Vanzellotti N, Fraga J, Pessoa F, Ferreira T, Amaral P. Biotransformation of Phytosterols into Androstenedione—A Technological Prospecting Study. *Molecules*. 2022;27(10):3164. doi:10.3390/molecules27103164
25. Mattison D, Parker R, Jackson L. *The Clinical Utility of Compounded Bioidentical Hormone Therapy*. (Mattison DR, Parker RM, Jackson LM, eds.). National Academies Press; 2020. doi:10.17226/25791
26. Vigesaa KA, Downhour NP, Chui MA, Cappellini L, Musil JD, McCallian DJ. Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy. *Int J Pharm Compd*. 2004;8(4):313-319.
27. White MD. *Bio-Identical Hormones Utilized for Treating Menopausal Symptoms*. San Jose State University; 2015. doi:10.31979/etd.e2ht-8zmu
28. Cho L, Kaunitz AM, Faubion SS, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? *Circulation*. 2023;147(7):597-610. doi:10.1161/CIRCULATIONAHA.122.061559
29. Gass MLS, Stuenkel CA, Utian WH, LaCroix A, Liu JH, Shifren JL. Use of compounded hormone therapy in the United States. *Menopause*. 2015;22(12):1276-1285. doi:10.1097/GME.0000000000000553
30. Vigneswaran K, Hamoda H. Hormone replacement therapy – Current recommendations. *Best Pract Res Clin Obstet Gynaecol*. 2022;81:8-21. doi:10.1016/j.bpobgyn.2021.12.001

31. Cameron CR, Cohen S, Sewell K, Lee M. The Art of Hormone Replacement Therapy (HRT) in Menopause Management. *J Pharm Pract*. 2024;37(3):736-740. doi:10.1177/08971900231167925

32. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. *Cochrane Database of Systematic Reviews*. 2004;2009(1). doi:10.1002/14651858.CD002978.pub2

33. Carter AE, Merriam S. Menopause. *Medical Clinics of North America*. 2023;107(2):199-212. doi:10.1016/j.mcna.2022.10.003

34. Zuo H, Sun A, Gao L, et al. Effect of Menopausal Hormone Therapy on Bone Mineral Density in Chinese Women: A 2-Year, Prospective, Open-Label, Randomized-Controlled Trial. *Medical Science Monitor*. 2019;25:819-826. doi:10.12659/MSM.912166

35. Barrett-Connor E, Wehren LE, Siris ES, et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. *Menopause*. 2003;10(5):412-419. doi:10.1097/01.GME.0000086467.82759.DA

36. The Writing Group of the PEPI Trial. Effects of Hormone Therapy on Bone Mineral Density. *JAMA*. 1996;276(17):1389. doi:10.1001/jama.1996.03540170033029

37. Azcoitia I, Arevalo MA, Garcia-Segura LM. Neural-derived estradiol regulates brain plasticity. *J Chem Neuroanat*. 2018;89:53-59. doi:10.1016/j.jchemneu.2017.04.004

38. Mosconi L, Rahman A, Diaz I, et al. Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. *PLoS One*. 2018;13(12):e0207885. doi:10.1371/journal.pone.0207885

39. Moradi F, Jahanian Sadatmahalleh S, Ziaei S. The effect of hormone replacement therapy on cognitive function in postmenopausal women: An RCT. *Int J Reprod Biomed*. 2018;16(12). doi:10.18502/ijrm.v16i12.3682

40. Ferreira Almeida C, Oliveira A, João Ramos M, Fernandes PA, Teixeira N, Amaral C. Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach? *Biochem Pharmacol*. 2020;177:113989. doi:10.1016/j.bcp.2020.113989

41. Katsyv I, Wang M, Song WM, et al. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer. *Oncotarget*. 2016;7(43):69592-69605. doi:10.18632/oncotarget.11870

42. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. *Crit Rev Oncol Hematol*. 2004;51(1):55-67. doi:10.1016/j.critrevonc.2004.02.001

43. Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. *Int J Mol Sci*. 2023;24(7):6834. doi:10.3390/ijms24076834

44. Khan MZI, Uzair M, Nazli A, Chen JZ. An overview on Estrogen receptors signaling and its ligands in breast cancer. *Eur J Med Chem*. 2022;241:114658. doi:10.1016/j.ejmech.2022.114658

45. Abenhaim HA, Suissa S, Azoulay L, Spence AR, Czuzoj-Shulman N, Tulandi T. Menopausal Hormone Therapy Formulation and Breast Cancer Risk. *Obstetrics & Gynecology*. 2022;139(6):1103-1110. doi:10.1097/AOG.0000000000004723

46. Shoker BS, Jarvis C, Clarke RB, et al. Estrogen Receptor-Positive Proliferating Cells in the Normal and Precancerous Breast. *Am J Pathol*. 1999;155(6):1811-1815. doi:10.1016/S0002-9440(10)65498-3

47. Martins V, Legroux N, Lascar M, Gluck M. Compounded bioidentical HRT improves quality of life and reduces menopausal symptoms. *Journal of Prescribing Practice*. 2020;2(7):384-390.

48. Langer RD, Hodis HN, Lobo RA, Allison MA. Hormone replacement therapy – where are we now? *Climacteric*. 2021;24(1):3-10. doi:10.1080/13697137.2020.1851183

49. Trabert B, Bauer DC, Buist DSM, et al. Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women. *JAMA Netw Open*. 2020;3(4):e203645.doi:10.1001/jamanetworkopen.2020.3645

50. Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. *Drug Des Devel Ther*. 2022;Volume 16:305-314. doi:10.2147/DDDT.S336643

51. Di Donato V, Palaia I, D'Aniello D, et al. Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review. *Oncology*. 2020;98(4):195-201. doi:10.1159/000505427

52. Gompel A. Progesterone and endometrial cancer. *Best Pract Res Clin Obstet Gynaecol*. 2020;69:95-107. doi:10.1016/j.bpobgyn.2020.05.003

53. Simon JA. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. *Climacteric*. 2012;15(sup1):3-10. doi:10.3109/13697137.2012.669332

54. Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. *Climacteric*. 2012;15(sup1):11-17. doi:10.3109/13697137.2012.669624

Together
we create the future
of personalizing medicine.

Fagron BV
Fascinatio Boulevard 350
3065 WB Rotterdam
The Netherlands

T +31 88 33 11 288
F +31 88 33 11 210
www.fagron.com

Fagron
personalizing
medicine